Page 94 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $3.80
52wk Low $0.66 Hoth Therapeutics, Inc. HOTH $1.15
1177 Avenue of the Americas
New York, NY 10036

(USD - in millions) hoththerapeutics.com
Market Cap 17.8
Enterprise 10.0
Basic Shares Out. 15.51 COMPANY OVERVIEW
Float 14.96
Institutional Holdings 8.61% Detailed Analysis:Channelchek.com
Short Interest 0.54
Avg. 90-Day Volume 1.16 At Hoth Therapeutics, we strive to develop innovative, impactful, and
ground-breaking treatments with a goal to improve patient quality of life.
We are a catalyst in early-stage pharmaceutical research and
development, elevating promising drugs from the bench to pre-clinical
EPS Data and clinical testing. Utilizing a patient-centric approach, we collaborate
and partner with a team of scientists, clinicians, and key opinion
2022 2023 2024 leaders to seek out and investigate medications that hold immense
CQ1 (2.75) (0.88) (0.46) potential to create breakthroughs and diversify treatment options.
CQ2 (2.25) (0.57) (0.24)

CQ3 (2.05) (0.60) (0.31)
CQ4 (2.72) (0.31) (0.32)
CY (9.50) (2.30) (1.28) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.54
ROE (ttm) -151.13
Debt-to-Total Cap. (mrq) 0.16
Fiscal Year End 31-Dec

1177 Avenue o ew York NY 10036
N
Key Executives
CEO: Knie, Robb
CFO: Briones, David
COO: Springer, Hayley
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures